# Valink Therapeutics

Source: https://onco.cc/companies/valink-therapeutics/  
OnCo record `valink-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Valink designs antibody-drug conjugates that grab two targets at once, aimed at solid tumours that immunotherapy does not reach.

## Summary

Valink Therapeutics discovers next-generation antibody-based therapeutics by combining multiple modifications, bispecificity, multivalency and payload conjugation, in a single discovery workflow, generating bispecific antibody-drug conjugates from known tumour targets with new mechanisms of action. Its stated focus is solid tumours poorly served by immunotherapy. Programmes are preclinical as far as public sources show; no sourced financing rounds are recorded.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: Boston, MA
- Type: biotech
- Website: https://www.valinktx.com

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/valink-therapeutics
- Official website: https://www.valinktx.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/valink-therapeutics.json